SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Sept. 18, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will host Science Day 2018 in New York City on Monday, September 24 th , beginning at approximately 10:00 A.M.
SAN DIEGO and SILVER SPRING, Md. , Sept. 17, 2018 /PRNewswire/ -- Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for North American rights to Samumed's SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF).
Exclusive license agreement for Treprostinil Technosphere®; $95 million in upfront and milestone payments Research agreement for additional products for additional $10 million SILVER SPRING, Md. and WESTLAKE VILLAGE, Calif. , Sept. 4, 2018 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq:
SILVER SPRING, Md. , Aug. 30, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) (" United Therapeutics ") today announced that it has closed the merger of SteadyMed Ltd. (NASDAQ: STDY) (" SteadyMed ") with a subsidiary of United Therapeutics .
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 8, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has entered into a Settlement Agreement with Watson Laboratories, Inc. ("Watson") resolving ongoing litigation concerning certain patents
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 8, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that preliminary analysis indicates that the FREEDOM-EV clinical study of Orenitram ® (treprostinil) extended-release tablets in patients suffering from
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 7, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that James Edgemond , Chief Financial Officer and Treasurer of United Therapeutics , will provide an overview and update on the company's business at the
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 1, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended June 30, 2018. "Our second quarter net revenues totaled $444 million and we are treating a larger number of
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , July 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration ( FDA ) of a New Drug Application (NDA) for the use of Remodulin (treprostinil) Injection in the
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , July 26, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its second quarter 2018 financial results before the market opens on Wednesday, August 1, 2018 .
